リキッドバイオプシーの世界市場：研究ツール・サービス・診断

世界のリキッドバイオプシーの市場規模は、2024年の46億米ドルから、予測期間中はCAGR 23.3％で推移し、2029年末には131億米ドルに達すると予測されています。

北米市場は、2024年の20億米ドルから、予測期間中はCAGR 23.1%で推移し、2029年末には57億米ドルに達すると予測されています。欧州市場は、2024年の13億米ドルから、CAGR 22.2%で推移し、2029年末には35億米ドルに達すると予測されます。

当レポートでは、世界のリキッドバイオプシーの市場を調査し、市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場概要

第2章 市場概要

• 概要
• リキッドバイオプシーと従来の生検
• リキッドバイオプシーで使用される分析物
• リキッドバイオプシーの新たな臨床応用

第3章 市場力学

• 市場力学
• 市場促進要因
• リキッドバイオプシーワークフロー技術の進歩
• 癌の発生率の増加
• 癌の早期発見への意識向上
• 組織生検の限界
• 市場抑制要因
• 特定のリキッドバイオプシーの感度の低下
• 市場機会
• 精密医療の重要性の高まり
• 中国などの新興国

第4章 新興技術と臨床試験

• リキッドバイオプシーにおけるナノテクノロジー
• リキッドバイオプシーにおけるマイクロ流体ベースのデバイス
• リキッドバイオプシー市場における臨床試験

第5章 市場セグメンテーション分析

• 市場動向
• セグメンテーションの内訳
• 世界のリキッドバイオプシー市場：用途別
• 非侵襲的出生前検査 (NIPT)
• 癌
• 臓器移植
• 世界のリキッドバイオプシー市場：分析目的別
• 早期発見・スクリーニング
• 監視
• 診断
• 治療ガイダンス
• 世界のリキッドバイオプシー市場：バイオマーカータイプ別
• 無細胞核酸
• 循環腫瘍細胞
• その他
• 世界のリキッドバイオプシー市場：分析プラットフォーム別
• 次世代シーケンシング (NGS)
• ポリメラーゼ連鎖反応 (PCR)
• その他
• 世界のリキッドバイオプシー市場：癌部位別
• 汎癌
• 大腸癌
• 乳癌
• 肺癌
• 膀胱癌
• 前立腺癌
• 血液癌
• 婦人科癌
• その他
• 地理的内訳
• 世界のリキッドバイオプシー市場：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域

第6章 競合情報

• 主要企業のランキング
• 比較分析

第7章 リキッドバイオプシー市場における持続可能性：ESGの観点

• ESG：イントロダクション
• リキッドバイオプシー業界におけるESGの実践
• 環境パフォーマンス
• 社会的パフォーマンス
• ガバナンスパフォーマンス
• ESGリスク評価
• BCCによる総論

第8章 付録

• 調査手法
• 略語
• 参考文献
• 企業プロファイル
• BIO-RAD LABORATORIES INC.
• BIO-TECHNE
• DXCOVER LTD.
• EXACT SCIENCES CORP.
• F. HOFFMANN-LA ROCHE LTD.
• FREEENOME HOLDINGS INC.
• GUARDANT HEALTH
• ILLUMINA INC.
• MYRIAD GENETICS INC.
• NATERA INC.
• NEOGENOMICS LABORATORIES
• NOVIGENIX SA
• PERSONALIS INC.
• QIAGEN
• THERMO FISHER SCIENTIFIC INC.

List of Tables

• Summary Table B : Global Market for Liquid Biopsy, by Region, Through 2029
• Summary Table A : Global Market for Liquid Biopsy, by Application, Through 2029
• Table 1 : Liquid Biopsy Sample Types and Characteristics
• Table 2 : Types of Analytes Used in Liquid Biopsy
• Table 3 : Comparison of ctDNA/cfDNA and CTCs
• Table 4 : List of Some Liquid Biopsy-based Available Tests Approved by FDA/CE-IVD
• Table 5 : Global Cancer Incidence and Mortality Cases, by WHO Region, 2022
• Table 6 : Emerging ctDNA and CTC Technologies for Liquid Biopsies
• Table 7 : List of Clinical Trials Conducted in Liquid Biopsies
• Table 8 : Global Market for Liquid Biopsy, by Application, Through 2029
• Table 9 : Global Market for Liquid Biopsy for NIPT, by Region, Through 2029
• Table 10 : Global Market for Liquid Biopsy for Cancer, by Region, Through 2029
• Table 11 : Global Market for Liquid Biopsy for Organ Transplantation, by Region, Through 2029
• Table 12 : Global Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
• Table 13 : Global Market for Liquid Biopsy for Early Detection/Screening, by Region, Through 2029
• Table 14 : Global Market for Liquid Biopsy for Monitoring, by Region, Through 2029
• Table 15 : Global Market for Liquid Biopsy for Diagnosis, by Region, Through 2029
• Table 16 : Global Market for Liquid Biopsy for Therapy Guidance, by Region, Through 2029
• Table 17 : Global Market for Liquid Biopsy, by Biomarker Type, Through 2029
• Table 18 : Global Market for Liquid Biopsy for Cell-free Nucleic Acids, by Region, Through 2029
• Table 19 : Global Market for Liquid Biopsy for Circulating Tumor Cells, by Region, Through 2029
• Table 20 : Global Market for Liquid Biopsy for Other Biomarker Types, by Region, Through 2029
• Table 21 : Global Market for Liquid Biopsy, by Analysis Platform, Through 2029
• Table 22 : Global Market for Liquid Biopsy for Next-Generation Sequencing, by Region, Through 2029
• Table 23 : Global Market for Liquid Biopsy for Polymerase Chain Reaction, by Region, Through 2029
• Table 24 : Global Market for Liquid Biopsy for Other Analysis Platforms, by Region, Through 2029
• Table 25 : Global Market for Liquid Biopsy, by Cancer Site, Through 2029
• Table 26 : Global Market for Liquid Biopsy for Pan-Cancer, by Region, Through 2029
• Table 27 : Global Market for Liquid Biopsy for Colorectal Cancer, by Region, Through 2029
• Table 28 : Global Market for Liquid Biopsy for Breast Cancer, by Region, Through 2029
• Table 29 : Global Market for Liquid Biopsy for Lung Cancer, by Region, Through 2029
• Table 30 : Global Market for Liquid Biopsy for Bladder Cancer, by Region, Through 2029
• Table 31 : Global Market for Liquid Biopsy for Prostate Cancer, by Region, Through 2029
• Table 32 : Global Market for Liquid Biopsy for Hematologic Cancer, by Region, Through 2029
• Table 33 : Global Market for Liquid Biopsy for Gynecologic Cancer, by Region, Through 2029
• Table 34 : Global Market for Liquid Biopsy for Other Cancers, by Region, Through 2029
• Table 35 : Global Market for Liquid Biopsy, by Region, Through 2029
• Table 36 : North American Market for Liquid Biopsy, by Application, Through 2029
• Table 37 : North American Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
• Table 38 : North American Market for Liquid Biopsy, by Biomarker Type, Through 2029
• Table 39 : North American Market for Liquid Biopsy, by Analysis Platform, Through 2029
• Table 40 : North American Market for Liquid Biopsy, by Cancer Site, Through 2029
• Table 41 : Estimated Incidence of Cancer Cases in the EU, by Country, 2022
• Table 42 : European Research Initiatives Focused on Personalized Medicine
• Table 43 : European Market for Liquid Biopsy, by Application, Through 2029
• Table 44 : European Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
• Table 45 : European Market for Liquid Biopsy, by Biomarker Type, Through 2029
• Table 46 : European Market for Liquid Biopsy, by Analysis Platform, Through 2029
• Table 47 : European Market for Liquid Biopsy, by Cancer Site, Through 2029
• Table 48 : Asia-Pacific Market for Liquid Biopsy, by Application, Through 2029
• Table 49 : Asia-Pacific Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
• Table 50 : Asia-Pacific Market for Liquid Biopsy, by Biomarker Type, Through 2029
• Table 51 : Asia-Pacific Market for Liquid Biopsy, by Analysis Platform, Through 2029
• Table 52 : Asia-Pacific Market for Liquid Biopsy, by Cancer Site, Through 2029
• Table 53 : RoW Market for Liquid Biopsy, by Application, Through 2029
• Table 54 : RoW Market for Liquid Biopsy, by Purpose of Analysis, Through 2029
• Table 55 : RoW Market for Liquid Biopsy, by Biomarker Type, Through 2029
• Table 56 : RoW Market for Liquid Biopsy, by Analysis Platform, Through 2029
• Table 57 : RoW Market for Liquid Biopsy, by Cancer Site, Through 2029
• Table 58 : Leading Companies in the Liquid Biopsy Market, 2023
• Table 59 : Comparison of Liquid Biopsy Tests for Early Detection of Single Cancers
• Table 60 : Key Focus Areas in ESG Metrics
• Table 61 : Environmental Performance Initiatives in the Liquid Biopsy Market
• Table 62 : Social Performance Initiatives in the Liquid Biopsy Market
• Table 63 : Governance Performance Initiatives in the Liquid Biopsy Market
• Table 64 : ESG Rankings for Leaders in the Market for Liquid Biopsy, 2024*
• Table 65 : Abbreviations Used in this Report
• Table 66 : Bio-Rad Laboratories Inc.: Company Snapshot
• Table 67 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2022 and 2023
• Table 68 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 69 : Bio-Rad Laboratories Inc.: News/Key Developments, 2022-2024
• Table 70 : Bio-Techne: Company Snapshot
• Table 71 : Bio-Techne: Financial Performance, FY 2022 and 2023
• Table 72 : Bio-Techne: Product Portfolio
• Table 73 : Bio-Techne: News/Key Developments, 2023 and 2024
• Table 74 : Dxcover Ltd.: Company Snapshot
• Table 75 : Dxcover Ltd.: Product Portfolio
• Table 76 : Dxcover Ltd.: News/Key Developments, 2023 and 2024
• Table 77 : Exact Sciences Corp.: Company Snapshot
• Table 78 : Exact Sciences Corp.: Financial Performance, FY 2022 and 2023
• Table 79 : Exact Sciences Corp.: Product Portfolio
• Table 80 : Exact Sciences Corp.: News/Key Developments, 2022-2024
• Table 81 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 82 : F. Hoffman-La Roche Ltd.: Financial Performance, FY 2022 and 2023
• Table 83 : F. Hoffman-La Roche Ltd.: Product Portfolio
• Table 84 : F. Hoffman-La Roche Ltd.: News/Key Developments, 2021-2023
• Table 85 : Freenome Holdings Inc.: Company Snapshot
• Table 86 : Freenome Holdings Inc.: Product Portfolio
• Table 87 : Freenome Holdings Inc.: News/Key Developments, 2023 and 2024
• Table 88 : Guardant Health: Company Snapshot
• Table 89 : Guardant Health: Financial Performance, FY 2022 and 2023
• Table 90 : Guardant Health: Product Portfolio
• Table 91 : Guardant Health: News/Key Developments, 2022-2024
• Table 92 : Illumina Inc.: Company Snapshot
• Table 93 : Illumina Inc.: Financial Performance, FY 2022 and 2023
• Table 94 : Illumina Inc.: Product Portfolio
• Table 95 : Illumina Inc.: News/Key Developments, 2022 and 2023
• Table 96 : Myriad Genetics Inc.: Company Snapshot
• Table 97 : Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023
• Table 98 : Myriad Genetics Inc: Product Portfolio
• Table 99 : Myriad Genetics Inc.: News/Key Developments, 2022-2024
• Table 100 : Natera Inc.: Company Snapshot
• Table 101 : Natera Inc.: Financial Performance, FY 2022 and 2023
• Table 102 : Natera Inc: Product Portfolio
• Table 103 : NeoGenomics Laboratories: Company Snapshot
• Table 104 : NeoGenomics Laboratories: Financial Performance, FY 2022 and 2023
• Table 105 : NeoGenomics Laboratories: Product Portfolio
• Table 106 : NeoGenomics Laboratories: News/Key Developments, 2022-2024
• Table 107 : Novigenix SA: Company Snapshot
• Table 108 : Novigenix SA: Product Portfolio
• Table 109 : Novigenix SA: News/Key Developments, 2024
• Table 110 : Personalis Inc.: Company Snapshot
• Table 111 : Personalis Inc.: Financial Performance, FY 2022 and 2023
• Table 112 : Personalis Inc.: Product Portfolio
• Table 113 : Personalis Inc.: News/Key Developments, 2023 and 2024
• Table 114 : QIAGEN: Company Snapshot
• Table 115 : QIAGEN: Financial Performance, FY 2022 and 2023
• Table 116 : QIAGEN: Product Portfolio
• Table 117 : QIAGEN: News/Key Developments, 2023 and 2024
• Table 118 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 119 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
• Table 120 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 121 : Thermo Fisher Scientific Inc.: News/Key Developments, 2022

List of Figures

• Summary Figure A : Global Market for Liquid Biopsy, by Application, 2021-2029
• Summary Figure B : Global Market for Liquid Biopsy, by Region, 2021-2029
• Figure 1 : Snapshot of the Market Dynamics for Liquid Biopsy
• Figure 2 : Global Market Shares of Liquid Biopsy, by Application 2024
• Figure 3 : Global Market for Liquid Biopsy for NIPT, by Region, 2021-2029
• Figure 4 : Estimated Number of New Cancer Cases Globally, 2022, 2045 and 2050
• Figure 5 : Global Market for Liquid Biopsy for Cancer, by Region, 2021-2029
• Figure 6 : Global Market for Liquid Biopsy for Organ Transplantation, by Region, 2021-2029
• Figure 7 : Global Market Shares of Liquid Biopsy, by Purpose of Analysis, 2024
• Figure 8 : Global Market for Liquid Biopsy for Early Detection/Screening, by Region, 2021-2029
• Figure 9 : Global Market for Liquid Biopsy for Monitoring, by Region, 2021-2029
• Figure 10 : Global Market for Liquid Biopsy for Monitoring, by Region, 2021-2029
• Figure 11 : Global Market for Liquid Biopsy for Therapy Guidance, by Region, 2021-2029
• Figure 12 : Global Market Shares of Liquid Biopsy, by Biomarker Type, 2024
• Figure 13 : Global Market for Liquid Biopsy for Cell-free Nucleic Acids, by Region, 2021-2029
• Figure 14 : Global Market for Liquid Biopsy for Circulating Tumor Cells, by Region, 2021-2029
• Figure 15 : Global Market for Liquid Biopsy for Other Biomarker Types, by Region, 2021-2029
• Figure 16 : Global Market Shares of Liquid Biopsy, by Analysis Platform, 2024
• Figure 17 : Global Market for Liquid Biopsy for Next-Generation Sequencing, by Region, 2021-2029
• Figure 18 : Global Market for Liquid Biopsy for Polymerase Chain Reaction, by Region, 2021-2029
• Figure 19 : Global Market for Liquid Biopsy for Other Analysis Platforms, by Region, 2021-2029
• Figure 20 : Global Market Shares of Liquid Biopsy, by Cancer Site, 2024
• Figure 21 : Global Market for Liquid Biopsy for Pan-Cancer, by Region, 2021-2029
• Figure 22 : Global Market for Liquid Biopsy for Colorectal Cancer, by Region, 2021-2029
• Figure 23 : Global Market for Liquid Biopsy for Breast Cancer, by Region, 2021-2029
• Figure 24 : Global Market for Liquid Biopsy for Lung Cancer, by Region, 2021-2029
• Figure 25 : Global Market for Liquid Biopsy for Bladder Cancer, by Region, 2021-2029
• Figure 26 : Global Market for Liquid Biopsy for Prostate Cancer, by Region, 2021-2029
• Figure 27 : Global Market for Liquid Biopsy for Hematologic Cancer, by Region, 2021-2029
• Figure 28 : Global Market for Liquid Biopsy for Gynecologic Cancer, by Region, 2021-2029
• Figure 29 : Global Market for Liquid Biopsy for Other Cancers, by Region, 2021-2029
• Figure 30 : Global Market Shares of Liquid Biopsy, by Region, 2024
• Figure 31 : U.S. Elderly Population (65 and Older), 2010-2050
• Figure 32 : North American Market for Liquid Biopsy, by Application, 2021-2029
• Figure 33 : North American Market for Liquid Biopsy, by Purpose of Analysis, 2021-2029
• Figure 34 : North American Market for Liquid Biopsy, by Biomarker Type, 2021-2029
• Figure 35 : North American Market for Liquid Biopsy, by Analysis Platform, 2021-2029
• Figure 36 : North American Market for Liquid Biopsy, by Cancer Site, 2021-2029
• Figure 37 : European Market for Liquid Biopsy, by Application, 2021-2029
• Figure 38 : European Market for Liquid Biopsy, by Purpose of Analysis, 2021-2029
• Figure 39 : European Market for Liquid Biopsy, by Biomarker Type, 2021-2029
• Figure 40 : European Market for Liquid Biopsy, by Analysis Platform, 2021-2029
• Figure 41 : European Market for Liquid Biopsy, by Cancer Site, 2021-2029
• Figure 42 : Asia-Pacific Market for Liquid Biopsy, by Application, 2021-2029
• Figure 43 : Asia-Pacific Market for Liquid Biopsy, by Purpose of Analysis, 2021-2029
• Figure 44 : Asia-Pacific Market for Liquid Biopsy, by Biomarker Type, 2021-2029
• Figure 45 : Asia-Pacific Market for Liquid Biopsy, by Analysis Platform, 2021-2029
• Figure 46 : Asia-Pacific Market for Liquid Biopsy, by Cancer Site, 2021-2029
• Figure 47 : RoW Market for Liquid Biopsy, by Application, 2021-2029
• Figure 48 : RoW Market for Liquid Biopsy, by Purpose of Analysis, 2021-2029
• Figure 49 : RoW Market for Liquid Biopsy, by Biomarker Type, 2021-2029
• Figure 50 : RoW Market for Liquid Biopsy, by Analysis Platform, 2021-2029
• Figure 51 : RoW Market for Liquid Biopsy, by Cancer Site, 2021-2029
• Figure 52 : How a Strong ESG Proposition Benefits Businesses?
• Figure 53 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 54 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 55 : Bio-Techne: Revenue Share, by Business Unit, FY 2023
• Figure 56 : Bio-Techne: Revenue Share, by Country/Region, FY 2023
• Figure 57 : Exact Sciences Corp.: Revenue Share, by Business Unit, FY 2023
• Figure 58 : Exact Sciences Corp.: Revenue Share, by Country/Region, FY 2023
• Figure 59 : F. Hoffman-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023
• Figure 60 : F. Hoffman-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023
• Figure 61 : Guardant Health: Revenue Share, by Business Unit, FY 2023
• Figure 62 : Guardant Health: Revenue Share, by Country/Region, FY 2023
• Figure 63 : Illumina Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 64 : Illumina Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 65 : Myriad Genetics Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 66 : Myriad Genetics Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 67 : Natera Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 68 : NeoGenomics Laboratories: Revenue Share, by Business Unit, FY 2023
• Figure 69 : Personalis Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 70 : QIAGEN: Revenue Share, by Business Unit, FY 2023
• Figure 71 : QIAGEN: Revenue Share, by Country/Region, FY 2023
• Figure 72 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 73 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023

The global market for liquid biopsy is expected to grow from $4.6 billion in 2024 and is projected to reach $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.

The North American liquid biopsy market is expected to grow from $2.0 billion in 2024 and is projected to reach $5.7 billion by the end of 2029, at a CAGR of 23.1% during the forecast period of 2024 to 2029.

The European liquid biopsy market is expected to grow from $1.3 billion in 2024 and is projected to reach $3.5 billion by the end of 2029, at a CAGR of 22.2% during the forecast period of 2024 to 2029.

Report Scope

This report provides an in-depth analysis of the global market for liquid biopsy tools, services and diagnostics, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. The report includes an overview of the industry structure and its competitive landscape. Leading market players' profiles, product offerings, financial information and recent market activities are provided. The report also assesses companies' business strategies and their effect in the face of the competitive environment. It details the global market based on application, purpose of analysis, biomarker type and platform. Regional analysis includes North America (U.S., Canada, Mexico), Europe (U.K., Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the world (South America, and the Middle East and Africa).

Report Includes

• 65 data tables and 58 additional tables
• Analyses of the trends in the global market for liquid biopsy research tools, services and diagnostics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
• Estimates of the market size and revenue growth prospects, along with a market share analysis by application, purpose of analysis, biomarker type, analysis platform (technology type) and region
• Examination of conventional biopsy methods and liquid biopsy enabling technologies
• Discussion of large-scale research initiatives
• Facts and figures pertaining to key market dynamics, technology advances, regulations, and the impact of macroeconomic factors
• Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Patent analysis, including key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Profiles of leading companies, including Exact Sciences Corp., Natera Inc., Guardant Health, Roche, and NeoGenomics Laboratories

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview
• Liquid Biopsy Versus Traditional Biopsy
• Analytes Used in Liquid Biopsy
• Emerging Clinical Applications of Liquid Biopsy

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Advances in Liquid Biopsy Workflow Technologies
• Increasing Incidence of Cancer
• Increasing Awareness of Early Cancer Detection
• Limitations of Tissue Biopsy
• Market Restraints
• Lower Sensitivity of Certain Liquid Biopsy Procedures
• Market Opportunities
• Growing Significance of Precision Medicine
• Emerging Economies such as China

Chapter 4 Emerging Technologies and Clinical Trials

• Nanotechnology in Liquid Biopsy
• Microfluidic-based Devices in Liquid Biopsy
• Clinical Trials in Liquid Biopsy Market

Chapter 5 Market Segmentation Analysis

• Market Trends
• Segmentation Breakdown
• Global Market for Liquid Biopsy by Application
• Non-invasive Prenatal Testing (NIPT)
• Cancer
• Organ Transplantation
• Global Market for Liquid Biopsy by Purpose of Analysis
• Early Detection/Screening
• Monitoring
• Diagnosis
• Therapy Guidance
• Global Market for Liquid Biopsy by Biomarker Type
• Cell-free Nucleic Acids
• Circulating Tumor Cells
• Other Biomarker Types
• Global Market for Liquid Biopsy by Analysis Platform
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Other Analysis Platforms
• Global Market for Liquid Biopsy by Cancer Site
• Pan-Cancer
• Colorectal Cancer
• Breast Cancer
• Lung Cancer
• Bladder Cancer
• Prostate Cancer
• Hematologic Cancer
• Gynecologic Cancer
• Other Cancers
• Geographic Breakdown
• Global Market for Liquid Biopsy by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Chapter 6 Competitive Intelligence

• Ranking of Leading Players
• Comparative Analysis

Chapter 7 Sustainability in the Liquid Biopsy Market: ESG Perspective

• Introduction to ESG
• ESG Practices in the Liquid Biopsy Industry
• Environmental Performance
• Social Performance
• Governance Performance
• ESG Risk Ratings
• Concluding Remarks from BCC Research

Chapter 8 Appendix

• Methodology
• Abbreviations
• References
• Company Profiles
• BIO-RAD LABORATORIES INC.
• BIO-TECHNE
• DXCOVER LTD.
• EXACT SCIENCES CORP.
• F. HOFFMANN-LA ROCHE LTD.
• FREEENOME HOLDINGS INC.
• GUARDANT HEALTH
• ILLUMINA INC.
• MYRIAD GENETICS INC.
• NATERA INC.
• NEOGENOMICS LABORATORIES
• NOVIGENIX SA
• PERSONALIS INC.
• QIAGEN
• THERMO FISHER SCIENTIFIC INC.